Incidence and survival for childhood cancer by endorsed non‐stage prognostic indicators in Australia

Abstract

AbstractBackgroundAn international expert panel recently recommended 15 ‘non‐stage prognostic indicators’ (NSPIs) across eight childhood cancers, classified as essential or additional, for collection in population‐based cancer registries. We aimed to describe the incidence distribution and survival of each of these NSPIs.ProceduresCases were extracted from the Australian Childhood Cancer Registry. The study cohort (n = 4187) comprised all children aged under 15 years diagnosed with an eligible cancer between 2010 and 2018, with follow‐up until 31 December 2020. NSPI data were collected directly from each patient's medical records. Differences in 5‐year relative survival were assessed using multivariable flexible parametric models, adjusted for sex and age group at diagnosis.ResultsThe availability of data varied, exceeding 85% for all essential NSPIs apart from histologic subtype for Wilms tumours (69%) and lineage for acute lymphoblastic leukaemia (78%). Information on additional NSPIs tended to be recorded less often, particularly cytogenetic subtype for non‐alveolar rhabdomyosarcoma (28%) and astrocytoma (4%). Eight NSPIs exhibited a significant difference in survival, with the largest disparity occurring among children with astrocytoma according to tumour grade (5‐year relative survival of 18% for grade IV disease compared with 99% for grade I disease; p < .001).ConclusionsOur findings demonstrate that most of the recommended NSPIs can be retrieved from medical records in Australia in recent years, allowing the capability of assessing survival within patient subgroups of clinical interest. Reporting of NSPI data has the capability to inform local and global understanding of population‐level disparities in childhood cancer survival.